Human conditions of insulin-like growth factor-I (IGF-I) deficiency
<p>Abstract</p> <p>Insulin-like growth factor I (IGF-I) is a polypeptide hormone produced mainly by the liver in response to the endocrine GH stimulus, but it is also secreted by multiple tissues for autocrine/paracrine purposes. IGF-I is partly responsible for systemic GH activiti...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-11-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | http://www.translational-medicine.com/content/10/1/224 |
| _version_ | 1828270764079448064 |
|---|---|
| author | Puche Juan E Castilla-Cortázar Inma |
| author_facet | Puche Juan E Castilla-Cortázar Inma |
| author_sort | Puche Juan E |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Insulin-like growth factor I (IGF-I) is a polypeptide hormone produced mainly by the liver in response to the endocrine GH stimulus, but it is also secreted by multiple tissues for autocrine/paracrine purposes. IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).</p> <p>IGF-I is a closely regulated hormone. Consequently, its logical therapeutical applications seems to be limited to restore physiological circulating levels in order to recover the clinical consequences of IGF-I deficiency, conditions where, despite continuous discrepancies, IGF-I treatment has never been related to oncogenesis. Currently the best characterized conditions of IGF-I deficiency are Laron Syndrome, in children; liver cirrhosis, in adults; aging including age-related-cardiovascular and neurological diseases; and more recently, intrauterine growth restriction.</p> <p>The aim of this review is to summarize the increasing list of roles of IGF-I, both in physiological and pathological conditions, underlying that its potential therapeutical options seem to be limited to those proven states of local or systemic IGF-I deficiency as a replacement treatment, rather than increasing its level upper the normal range.</p> |
| first_indexed | 2024-04-13T05:46:22Z |
| format | Article |
| id | doaj.art-02f0d020f648438e984d613fdfc7e5ae |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-04-13T05:46:22Z |
| publishDate | 2012-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-02f0d020f648438e984d613fdfc7e5ae2022-12-22T02:59:56ZengBMCJournal of Translational Medicine1479-58762012-11-0110122410.1186/1479-5876-10-224Human conditions of insulin-like growth factor-I (IGF-I) deficiencyPuche Juan ECastilla-Cortázar Inma<p>Abstract</p> <p>Insulin-like growth factor I (IGF-I) is a polypeptide hormone produced mainly by the liver in response to the endocrine GH stimulus, but it is also secreted by multiple tissues for autocrine/paracrine purposes. IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).</p> <p>IGF-I is a closely regulated hormone. Consequently, its logical therapeutical applications seems to be limited to restore physiological circulating levels in order to recover the clinical consequences of IGF-I deficiency, conditions where, despite continuous discrepancies, IGF-I treatment has never been related to oncogenesis. Currently the best characterized conditions of IGF-I deficiency are Laron Syndrome, in children; liver cirrhosis, in adults; aging including age-related-cardiovascular and neurological diseases; and more recently, intrauterine growth restriction.</p> <p>The aim of this review is to summarize the increasing list of roles of IGF-I, both in physiological and pathological conditions, underlying that its potential therapeutical options seem to be limited to those proven states of local or systemic IGF-I deficiency as a replacement treatment, rather than increasing its level upper the normal range.</p>http://www.translational-medicine.com/content/10/1/224Laron syndromeLiver cirrhosisAgingOxidative stressGH/IGF-I axisMitochondrial dysfunctionCellular protectionGrowthCancer protection |
| spellingShingle | Puche Juan E Castilla-Cortázar Inma Human conditions of insulin-like growth factor-I (IGF-I) deficiency Journal of Translational Medicine Laron syndrome Liver cirrhosis Aging Oxidative stress GH/IGF-I axis Mitochondrial dysfunction Cellular protection Growth Cancer protection |
| title | Human conditions of insulin-like growth factor-I (IGF-I) deficiency |
| title_full | Human conditions of insulin-like growth factor-I (IGF-I) deficiency |
| title_fullStr | Human conditions of insulin-like growth factor-I (IGF-I) deficiency |
| title_full_unstemmed | Human conditions of insulin-like growth factor-I (IGF-I) deficiency |
| title_short | Human conditions of insulin-like growth factor-I (IGF-I) deficiency |
| title_sort | human conditions of insulin like growth factor i igf i deficiency |
| topic | Laron syndrome Liver cirrhosis Aging Oxidative stress GH/IGF-I axis Mitochondrial dysfunction Cellular protection Growth Cancer protection |
| url | http://www.translational-medicine.com/content/10/1/224 |
| work_keys_str_mv | AT puchejuane humanconditionsofinsulinlikegrowthfactoriigfideficiency AT castillacortazarinma humanconditionsofinsulinlikegrowthfactoriigfideficiency |